Aditya Singh
@drsinghaditya.bsky.social
PGY-2 IM Resident | Aspiring Pulmonologist & Intensivist | #MedEd #CritCare | Views my own
🚨STEMI + multivessel disease: Immediate or Deferred Nonculprit Lesion PCI🫀
@nejm.org #UPDATE
🫀Immediate iFR-guided PCI ≈ Deferred MRI-guided PCI at 3 yrs
⚡No difference in death, MI, or HF hospitalization (HR 0.95, p=0.81)
🧠 Stroke/TIA lower with iFR
tinyurl.com/ystr7kvm
@nejm.org #UPDATE
🫀Immediate iFR-guided PCI ≈ Deferred MRI-guided PCI at 3 yrs
⚡No difference in death, MI, or HF hospitalization (HR 0.95, p=0.81)
🧠 Stroke/TIA lower with iFR
tinyurl.com/ystr7kvm
October 28, 2025 at 11:10 PM
🚨STEMI + multivessel disease: Immediate or Deferred Nonculprit Lesion PCI🫀
@nejm.org #UPDATE
🫀Immediate iFR-guided PCI ≈ Deferred MRI-guided PCI at 3 yrs
⚡No difference in death, MI, or HF hospitalization (HR 0.95, p=0.81)
🧠 Stroke/TIA lower with iFR
tinyurl.com/ystr7kvm
@nejm.org #UPDATE
🫀Immediate iFR-guided PCI ≈ Deferred MRI-guided PCI at 3 yrs
⚡No difference in death, MI, or HF hospitalization (HR 0.95, p=0.81)
🧠 Stroke/TIA lower with iFR
tinyurl.com/ystr7kvm
🚨AI-ECG analysis for STEMI triage (JACC 2025)🫀⚡️ #JournalWatch
✅ ↑ Sensitivity 92% vs 71%
✅ ↓ False activations 7.9% vs 41.8%
✅ Better detection of LCx (40.6%) misses
#Cardiology #STEMI #AI @jaccjournals.bsky.social
tinyurl.com/54m23uj4
✅ ↑ Sensitivity 92% vs 71%
✅ ↓ False activations 7.9% vs 41.8%
✅ Better detection of LCx (40.6%) misses
#Cardiology #STEMI #AI @jaccjournals.bsky.social
tinyurl.com/54m23uj4
October 28, 2025 at 11:02 PM
🚨AI-ECG analysis for STEMI triage (JACC 2025)🫀⚡️ #JournalWatch
✅ ↑ Sensitivity 92% vs 71%
✅ ↓ False activations 7.9% vs 41.8%
✅ Better detection of LCx (40.6%) misses
#Cardiology #STEMI #AI @jaccjournals.bsky.social
tinyurl.com/54m23uj4
✅ ↑ Sensitivity 92% vs 71%
✅ ↓ False activations 7.9% vs 41.8%
✅ Better detection of LCx (40.6%) misses
#Cardiology #STEMI #AI @jaccjournals.bsky.social
tinyurl.com/54m23uj4
Thoughts?-POCUS for Setting PEEP🫁
🫧Lung US→Detect recruitment, monitor aeration
💪Diaphragm US→Track diaphragm geometry, contractility, predict NIV/weaning outcomes.
📈 Integrating both helps balance recruitment vs overdistension.
tinyurl.com/35ttec4f
🫧Lung US→Detect recruitment, monitor aeration
💪Diaphragm US→Track diaphragm geometry, contractility, predict NIV/weaning outcomes.
📈 Integrating both helps balance recruitment vs overdistension.
tinyurl.com/35ttec4f
October 28, 2025 at 2:22 AM
Thoughts?-POCUS for Setting PEEP🫁
🫧Lung US→Detect recruitment, monitor aeration
💪Diaphragm US→Track diaphragm geometry, contractility, predict NIV/weaning outcomes.
📈 Integrating both helps balance recruitment vs overdistension.
tinyurl.com/35ttec4f
🫧Lung US→Detect recruitment, monitor aeration
💪Diaphragm US→Track diaphragm geometry, contractility, predict NIV/weaning outcomes.
📈 Integrating both helps balance recruitment vs overdistension.
tinyurl.com/35ttec4f
🫀SCCM 2024 - Guidelines on Adult Critical Care Ultrasonography 🏥:
Conditional recommendations-
🫢 Acute dyspnea / resp failure
💧 Targeted volume management
❤️ Cardiogenic shock
🦠 Septic shock
+/-⚖️ Cardiac arrest
#POCUS #ICU #PCCM @sccmcriticalcare.bsky.social
tinyurl.com/5a7w3k8k
Conditional recommendations-
🫢 Acute dyspnea / resp failure
💧 Targeted volume management
❤️ Cardiogenic shock
🦠 Septic shock
+/-⚖️ Cardiac arrest
#POCUS #ICU #PCCM @sccmcriticalcare.bsky.social
tinyurl.com/5a7w3k8k
October 28, 2025 at 2:10 AM
🫀SCCM 2024 - Guidelines on Adult Critical Care Ultrasonography 🏥:
Conditional recommendations-
🫢 Acute dyspnea / resp failure
💧 Targeted volume management
❤️ Cardiogenic shock
🦠 Septic shock
+/-⚖️ Cardiac arrest
#POCUS #ICU #PCCM @sccmcriticalcare.bsky.social
tinyurl.com/5a7w3k8k
Conditional recommendations-
🫢 Acute dyspnea / resp failure
💧 Targeted volume management
❤️ Cardiogenic shock
🦠 Septic shock
+/-⚖️ Cardiac arrest
#POCUS #ICU #PCCM @sccmcriticalcare.bsky.social
tinyurl.com/5a7w3k8k
🫀💊Aspirin & Oral Anticaogulation in Chronic Coronary Syndrome /
🧑🎓AQUATIC Trial (NEJM Oct 2025):
✅Adding aspirin ↑ CV events, ↑ mortality, & ↑ major bleeding vs placebo
👉 No ischemic benefit
❤️🔥More harm
@nejm.org #Cardio #updates
tinyurl.com/2zc5zh38
🧑🎓AQUATIC Trial (NEJM Oct 2025):
✅Adding aspirin ↑ CV events, ↑ mortality, & ↑ major bleeding vs placebo
👉 No ischemic benefit
❤️🔥More harm
@nejm.org #Cardio #updates
tinyurl.com/2zc5zh38
October 27, 2025 at 3:53 PM
🫀💊Aspirin & Oral Anticaogulation in Chronic Coronary Syndrome /
🧑🎓AQUATIC Trial (NEJM Oct 2025):
✅Adding aspirin ↑ CV events, ↑ mortality, & ↑ major bleeding vs placebo
👉 No ischemic benefit
❤️🔥More harm
@nejm.org #Cardio #updates
tinyurl.com/2zc5zh38
🧑🎓AQUATIC Trial (NEJM Oct 2025):
✅Adding aspirin ↑ CV events, ↑ mortality, & ↑ major bleeding vs placebo
👉 No ischemic benefit
❤️🔥More harm
@nejm.org #Cardio #updates
tinyurl.com/2zc5zh38
💊🫁Therapies in CTD-ILD (ATS 2020):
🔹Steroids- acute inflammation
🔹Mycophenolate/Cyclophosphamide- immunosuppression backbone
🔹Rituximab/Tacrolimus- for refractory disease
🔹Nintedanib/Tocilizumab- antifibrotic & targeted
#ILD #PulmCC @atscommunity.bsky.social
tinyurl.com/kyyvnftu
🔹Steroids- acute inflammation
🔹Mycophenolate/Cyclophosphamide- immunosuppression backbone
🔹Rituximab/Tacrolimus- for refractory disease
🔹Nintedanib/Tocilizumab- antifibrotic & targeted
#ILD #PulmCC @atscommunity.bsky.social
tinyurl.com/kyyvnftu
October 25, 2025 at 11:42 PM
💊🫁Therapies in CTD-ILD (ATS 2020):
🔹Steroids- acute inflammation
🔹Mycophenolate/Cyclophosphamide- immunosuppression backbone
🔹Rituximab/Tacrolimus- for refractory disease
🔹Nintedanib/Tocilizumab- antifibrotic & targeted
#ILD #PulmCC @atscommunity.bsky.social
tinyurl.com/kyyvnftu
🔹Steroids- acute inflammation
🔹Mycophenolate/Cyclophosphamide- immunosuppression backbone
🔹Rituximab/Tacrolimus- for refractory disease
🔹Nintedanib/Tocilizumab- antifibrotic & targeted
#ILD #PulmCC @atscommunity.bsky.social
tinyurl.com/kyyvnftu
🫁Connective Tissue Disease Associated ILD (ATS 2020)
🔹RA-UIP pattern
🔹SSc-NSIP
🔹IIM (Idio Inflam Myopathy)– NSIP + OP overlap
#Updates
#PulmCC #Rheum #ILD @atscommunity.bsky.social
tinyurl.com/kyyvnftu
🔹RA-UIP pattern
🔹SSc-NSIP
🔹IIM (Idio Inflam Myopathy)– NSIP + OP overlap
#Updates
#PulmCC #Rheum #ILD @atscommunity.bsky.social
tinyurl.com/kyyvnftu
October 25, 2025 at 11:34 PM
🫁Connective Tissue Disease Associated ILD (ATS 2020)
🔹RA-UIP pattern
🔹SSc-NSIP
🔹IIM (Idio Inflam Myopathy)– NSIP + OP overlap
#Updates
#PulmCC #Rheum #ILD @atscommunity.bsky.social
tinyurl.com/kyyvnftu
🔹RA-UIP pattern
🔹SSc-NSIP
🔹IIM (Idio Inflam Myopathy)– NSIP + OP overlap
#Updates
#PulmCC #Rheum #ILD @atscommunity.bsky.social
tinyurl.com/kyyvnftu
Big week ahead at #CHEST2025 🫁🧑🔬🥼✨
Presenting multiple 🪧 posters, a 🎤 rapid-fire oral presentation, and honored to be a 🏅 semifinalist for the Top Scientific Abstract Poster Award!
Grateful & excited to share our work 🙌
#PCCM #CHESTSoMe @accpchest.bsky.social
Presenting multiple 🪧 posters, a 🎤 rapid-fire oral presentation, and honored to be a 🏅 semifinalist for the Top Scientific Abstract Poster Award!
Grateful & excited to share our work 🙌
#PCCM #CHESTSoMe @accpchest.bsky.social
October 18, 2025 at 5:15 PM
Big week ahead at #CHEST2025 🫁🧑🔬🥼✨
Presenting multiple 🪧 posters, a 🎤 rapid-fire oral presentation, and honored to be a 🏅 semifinalist for the Top Scientific Abstract Poster Award!
Grateful & excited to share our work 🙌
#PCCM #CHESTSoMe @accpchest.bsky.social
Presenting multiple 🪧 posters, a 🎤 rapid-fire oral presentation, and honored to be a 🏅 semifinalist for the Top Scientific Abstract Poster Award!
Grateful & excited to share our work 🙌
#PCCM #CHESTSoMe @accpchest.bsky.social
Made it to Chicago for #CHEST2025! 🫁🌇
Honored to be part of the Social Media team - can’t wait to dive into sessions, meet colleagues & share it all with you. #CHESTConference #PulmCC #MedTwitter #CHESTSoMe @accpchest.bsky.social
Honored to be part of the Social Media team - can’t wait to dive into sessions, meet colleagues & share it all with you. #CHESTConference #PulmCC #MedTwitter #CHESTSoMe @accpchest.bsky.social
October 17, 2025 at 3:56 PM
Made it to Chicago for #CHEST2025! 🫁🌇
Honored to be part of the Social Media team - can’t wait to dive into sessions, meet colleagues & share it all with you. #CHESTConference #PulmCC #MedTwitter #CHESTSoMe @accpchest.bsky.social
Honored to be part of the Social Media team - can’t wait to dive into sessions, meet colleagues & share it all with you. #CHESTConference #PulmCC #MedTwitter #CHESTSoMe @accpchest.bsky.social
🫁ARDS Mx (ATS 2024):
✅Lung-protective vent(Vt 4–8 mL/kg PBW, Pplat <30)
✅Prone >12 h/day for severe ARDS
🟡Consider: Steroids, VV-ECMO, NMB, higher PEEP (no LRMs)
🚫No HFOV & prolonged LRMs
@atscommunity.bsky.social
#ARDS #CriticalCare #Pulm #ICU
tinyurl.com/sxuwd3f5
✅Lung-protective vent(Vt 4–8 mL/kg PBW, Pplat <30)
✅Prone >12 h/day for severe ARDS
🟡Consider: Steroids, VV-ECMO, NMB, higher PEEP (no LRMs)
🚫No HFOV & prolonged LRMs
@atscommunity.bsky.social
#ARDS #CriticalCare #Pulm #ICU
tinyurl.com/sxuwd3f5
October 17, 2025 at 2:58 PM
🫁ARDS Mx (ATS 2024):
✅Lung-protective vent(Vt 4–8 mL/kg PBW, Pplat <30)
✅Prone >12 h/day for severe ARDS
🟡Consider: Steroids, VV-ECMO, NMB, higher PEEP (no LRMs)
🚫No HFOV & prolonged LRMs
@atscommunity.bsky.social
#ARDS #CriticalCare #Pulm #ICU
tinyurl.com/sxuwd3f5
✅Lung-protective vent(Vt 4–8 mL/kg PBW, Pplat <30)
✅Prone >12 h/day for severe ARDS
🟡Consider: Steroids, VV-ECMO, NMB, higher PEEP (no LRMs)
🚫No HFOV & prolonged LRMs
@atscommunity.bsky.social
#ARDS #CriticalCare #Pulm #ICU
tinyurl.com/sxuwd3f5
Tirzepatide-OSA (NEJM 2024)💉🛏️💤
⚕️FDA Approves First Medication for Obstructive Sleep Apnea
💊Drug: Weekly tirzepatide > placebo
🧑🤝🧑Pop: OSA + obesity (no non-obese)
👉Effect: ↓AHI, ↓wt, ↓SBP, ↓hsCRP @ 52wks
@nejm.org @fda.gov
tinyurl.com/mrytwruc
⚕️FDA Approves First Medication for Obstructive Sleep Apnea
💊Drug: Weekly tirzepatide > placebo
🧑🤝🧑Pop: OSA + obesity (no non-obese)
👉Effect: ↓AHI, ↓wt, ↓SBP, ↓hsCRP @ 52wks
@nejm.org @fda.gov
tinyurl.com/mrytwruc
October 15, 2025 at 10:01 PM
Tirzepatide-OSA (NEJM 2024)💉🛏️💤
⚕️FDA Approves First Medication for Obstructive Sleep Apnea
💊Drug: Weekly tirzepatide > placebo
🧑🤝🧑Pop: OSA + obesity (no non-obese)
👉Effect: ↓AHI, ↓wt, ↓SBP, ↓hsCRP @ 52wks
@nejm.org @fda.gov
tinyurl.com/mrytwruc
⚕️FDA Approves First Medication for Obstructive Sleep Apnea
💊Drug: Weekly tirzepatide > placebo
🧑🤝🧑Pop: OSA + obesity (no non-obese)
👉Effect: ↓AHI, ↓wt, ↓SBP, ↓hsCRP @ 52wks
@nejm.org @fda.gov
tinyurl.com/mrytwruc
High Dose IV Vit B12 in Septic Shock, Phase 2 Trial (Pilot):
🧑🔧Mechanism: H₂S scavenger → ↑vascular tone
💊Intervention: 5 g IV hydroxocobalamin ×1 vs placebo
👉Result: ↓vasopressor need (−36% vs 4%); safe & feasible
tinyurl.com/3de9k7c8 @accpchest.bsky.social #Sepsis
🧑🔧Mechanism: H₂S scavenger → ↑vascular tone
💊Intervention: 5 g IV hydroxocobalamin ×1 vs placebo
👉Result: ↓vasopressor need (−36% vs 4%); safe & feasible
tinyurl.com/3de9k7c8 @accpchest.bsky.social #Sepsis
October 15, 2025 at 2:54 PM
High Dose IV Vit B12 in Septic Shock, Phase 2 Trial (Pilot):
🧑🔧Mechanism: H₂S scavenger → ↑vascular tone
💊Intervention: 5 g IV hydroxocobalamin ×1 vs placebo
👉Result: ↓vasopressor need (−36% vs 4%); safe & feasible
tinyurl.com/3de9k7c8 @accpchest.bsky.social #Sepsis
🧑🔧Mechanism: H₂S scavenger → ↑vascular tone
💊Intervention: 5 g IV hydroxocobalamin ×1 vs placebo
👉Result: ↓vasopressor need (−36% vs 4%); safe & feasible
tinyurl.com/3de9k7c8 @accpchest.bsky.social #Sepsis
Pulm-renal syndrome serology (ERS 2023)🫘📷💊
🩸ANCA Vasculitis:GPA→PR3+, MPA→MPO+, EGPA→MPO±
🩸Anti-GBM: Ab 95–100% sens/spec
🩸CTD: SLE→dsDNA/Sm/C1q; APS→aCL/Lupus AntiCoag; RA→RF/anti-CCP; MCTD→Anti-RNP
@europeanrespsoc.bsky.social
tinyurl.com/4zz3fh74
🩸ANCA Vasculitis:GPA→PR3+, MPA→MPO+, EGPA→MPO±
🩸Anti-GBM: Ab 95–100% sens/spec
🩸CTD: SLE→dsDNA/Sm/C1q; APS→aCL/Lupus AntiCoag; RA→RF/anti-CCP; MCTD→Anti-RNP
@europeanrespsoc.bsky.social
tinyurl.com/4zz3fh74
October 15, 2025 at 5:22 AM
Pulm-renal syndrome serology (ERS 2023)🫘📷💊
🩸ANCA Vasculitis:GPA→PR3+, MPA→MPO+, EGPA→MPO±
🩸Anti-GBM: Ab 95–100% sens/spec
🩸CTD: SLE→dsDNA/Sm/C1q; APS→aCL/Lupus AntiCoag; RA→RF/anti-CCP; MCTD→Anti-RNP
@europeanrespsoc.bsky.social
tinyurl.com/4zz3fh74
🩸ANCA Vasculitis:GPA→PR3+, MPA→MPO+, EGPA→MPO±
🩸Anti-GBM: Ab 95–100% sens/spec
🩸CTD: SLE→dsDNA/Sm/C1q; APS→aCL/Lupus AntiCoag; RA→RF/anti-CCP; MCTD→Anti-RNP
@europeanrespsoc.bsky.social
tinyurl.com/4zz3fh74
Pulmonary-renal syndrome Tx (ERS 2023)🫘🫁💊
🙀Induction: Steroids+CYC/RTX±PLEX ±IVIG/AC (APS)
😼Maintenance: Per etiology-Steroids/AZA/MTX/CYC/RTX
@europeanrespsoc.bsky.social doi.org/10.1183/2073...
🙀Induction: Steroids+CYC/RTX±PLEX ±IVIG/AC (APS)
😼Maintenance: Per etiology-Steroids/AZA/MTX/CYC/RTX
@europeanrespsoc.bsky.social doi.org/10.1183/2073...
October 15, 2025 at 5:11 AM
Pulmonary-renal syndrome Tx (ERS 2023)🫘🫁💊
🙀Induction: Steroids+CYC/RTX±PLEX ±IVIG/AC (APS)
😼Maintenance: Per etiology-Steroids/AZA/MTX/CYC/RTX
@europeanrespsoc.bsky.social doi.org/10.1183/2073...
🙀Induction: Steroids+CYC/RTX±PLEX ±IVIG/AC (APS)
😼Maintenance: Per etiology-Steroids/AZA/MTX/CYC/RTX
@europeanrespsoc.bsky.social doi.org/10.1183/2073...
Fleischner 2017- Solid Pulm Nodule🫁
👉<6 mm:Low risk-no FU;High risk-optional CT@ 12 mo
👉6–8 mm:CT@ 6-12 mo→ consider @ 18–24 mo
👉>8 mm:CT@ 3 mo±PET/CT or biopsy
⚡️Use most suspicious nodule if multiple
🤯risk = smoker/upper lobe/morphology @rsnasky.bsky.social
doi.org/10.1148/radi...
👉<6 mm:Low risk-no FU;High risk-optional CT@ 12 mo
👉6–8 mm:CT@ 6-12 mo→ consider @ 18–24 mo
👉>8 mm:CT@ 3 mo±PET/CT or biopsy
⚡️Use most suspicious nodule if multiple
🤯risk = smoker/upper lobe/morphology @rsnasky.bsky.social
doi.org/10.1148/radi...
October 15, 2025 at 4:48 AM
Fleischner 2017- Solid Pulm Nodule🫁
👉<6 mm:Low risk-no FU;High risk-optional CT@ 12 mo
👉6–8 mm:CT@ 6-12 mo→ consider @ 18–24 mo
👉>8 mm:CT@ 3 mo±PET/CT or biopsy
⚡️Use most suspicious nodule if multiple
🤯risk = smoker/upper lobe/morphology @rsnasky.bsky.social
doi.org/10.1148/radi...
👉<6 mm:Low risk-no FU;High risk-optional CT@ 12 mo
👉6–8 mm:CT@ 6-12 mo→ consider @ 18–24 mo
👉>8 mm:CT@ 3 mo±PET/CT or biopsy
⚡️Use most suspicious nodule if multiple
🤯risk = smoker/upper lobe/morphology @rsnasky.bsky.social
doi.org/10.1148/radi...
AI can predict AKI 24-48h before changes in s.Cr levels and identify sub-phenotypes with distinct characteristics and outcomes.
Promise is huge but validation, ethics & data quality remain key.
#Nephrology #AI @jasminenephro.bsky.social Nephro DOI: 10.1097/MCC.0000000000001202
Promise is huge but validation, ethics & data quality remain key.
#Nephrology #AI @jasminenephro.bsky.social Nephro DOI: 10.1097/MCC.0000000000001202
October 14, 2025 at 3:28 AM
AI can predict AKI 24-48h before changes in s.Cr levels and identify sub-phenotypes with distinct characteristics and outcomes.
Promise is huge but validation, ethics & data quality remain key.
#Nephrology #AI @jasminenephro.bsky.social Nephro DOI: 10.1097/MCC.0000000000001202
Promise is huge but validation, ethics & data quality remain key.
#Nephrology #AI @jasminenephro.bsky.social Nephro DOI: 10.1097/MCC.0000000000001202
🚨PEERLESS Trial🚨
Large-bore mechanical thrombectomy (LBMT) vs catheter-directed thrombolysis (CDT) for intermediate-risk PE.
LBMT✅=fewer clinical deteriorations, less ICU use, and shorter hospital stay with no ↑ in mortality or bleeding. @ahascience.bsky.social
www.ahajournals.org/doi/10.1161/...
Large-bore mechanical thrombectomy (LBMT) vs catheter-directed thrombolysis (CDT) for intermediate-risk PE.
LBMT✅=fewer clinical deteriorations, less ICU use, and shorter hospital stay with no ↑ in mortality or bleeding. @ahascience.bsky.social
www.ahajournals.org/doi/10.1161/...
October 14, 2025 at 2:50 AM
🚨PEERLESS Trial🚨
Large-bore mechanical thrombectomy (LBMT) vs catheter-directed thrombolysis (CDT) for intermediate-risk PE.
LBMT✅=fewer clinical deteriorations, less ICU use, and shorter hospital stay with no ↑ in mortality or bleeding. @ahascience.bsky.social
www.ahajournals.org/doi/10.1161/...
Large-bore mechanical thrombectomy (LBMT) vs catheter-directed thrombolysis (CDT) for intermediate-risk PE.
LBMT✅=fewer clinical deteriorations, less ICU use, and shorter hospital stay with no ↑ in mortality or bleeding. @ahascience.bsky.social
www.ahajournals.org/doi/10.1161/...
Counting down to #CHEST2025! As Social Media Ambassador, I'm geeking out over sessions on AI and newer advances. What's the 'next big problem' in medicine we need to solve? Will be tweeting live from Chicago! Oct 19-22. #CHESTSoMe #MedEd #ARDS #CHEST2025
@accpchest.bsky.social
@accpchest.bsky.social
October 14, 2025 at 2:34 AM
Counting down to #CHEST2025! As Social Media Ambassador, I'm geeking out over sessions on AI and newer advances. What's the 'next big problem' in medicine we need to solve? Will be tweeting live from Chicago! Oct 19-22. #CHESTSoMe #MedEd #ARDS #CHEST2025
@accpchest.bsky.social
@accpchest.bsky.social